tumors

BWX Technologies Inc's (NYSE: BWXT) subsidiary BWXT Medical Ltd. has agreed with Bayer AG (OTC: BAYRY) to develop Actinium-225 (Ac-225) supply and further partnering opportunities on finished products. The financial terms of the agreement were not disclosed. The...

The FDA on Friday approved Merck & Co Inc's (NYSE: MRK) belzutifan for patients with the rare disorder known as von Hippel-Lindau (VHL) disease.  VHL is a rare genetic disease that causes tumors and cysts to grow throughout the body. Belzutifan was one of the most...

Epizyme Inc (NASDAQ: EPZM) and HUTCHMED (China) Limited (NASDAQ: HCM) have collaborated to research, develop, manufacture, and commercialize Tazverik (tazemetostat) in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. Tazverik is a methyltransferase...

Auris Medical Holding Ltd (NASDAQ: EARS) has announced the publication of positive results from an in vivo study employing its OligoPhore technology in Adult T-cell Leukemia-Lymphoma (ATLL). The article was published in Nanomaterials, an international peer-reviewed open-access...

Novartis AG (NYSE: NVS) reported the final analysis from the NETTER-1 phase 3 study comparing Lutathera plus 30 mg Sandostatin LAR (octreotide) to 60 mg octreotide LAR in patients with midgut neuroendocrine tumors. Lutathera failed to significantly prolong the lives of patients with...

Oric Pharmaceuticals Inc (NASDAQ: ORIC) has announced initial data from an ongoing Phase 1b study evaluating ORIC-101 in combination with nab-paclitaxel, in advanced solid tumors. Data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. As of the...

Phio Pharmaceuticals Corp (NASDAQ: PHIO) stock falls despite the company announcing positive new in vivo data showing that PH-762 significantly enhanced the antitumor efficacy of HER2-targeted CAR-T cells (HER2CART) in solid tumors. Compared to untreated, HER2CART cells treated...

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-developed with Astellas Pharma (OTCMKTS: ALPMF) The data were presented at the American Society for Cell and Gene...

The FDA kicked off a three-day meet to reexamine the accelerated approvals of immuno-oncology drugs with confirmatory trials that have not met their primary endpoint(s) and have yet to gain regular approvals. FDA’s Oncologic Drugs Advisory Committee (ODAC) started the meet with Roche...

Hoth Therapeutics Inc (NASDAQ: HOTH) has reported that its novel anti-cancer therapeutic demonstrated positive results in humanized mast-cell neoplasm animal models for aggressive, mast cell-derived cancers such as mast cell leukemia and mast cell sarcoma. The anti-cancer...

Phio Pharmaceuticals Corp (NASDAQ: PHIO) announced new preclinical data for the Intasyl platform in tumor settings. These data were presented today during the AACR Annual Meeting 2021. Data showed that local intratumoral (IT) delivery with the murine PD-1 targeting Intasyl (mPH...

Goldman Sachs said evidence of Merck & Co., Inc. (NYSE: MRK)'s Keytruda benefit as a single agent continues to build as registrational monotherapy studies read out. Merck's data presented at ASCO (American Society of Clinical Oncology) include updates on new tumors, existing tumors and...